|
ES2237576T3
(es)
*
|
2000-05-26 |
2005-08-01 |
Schering Corporation |
Antagonistas del receptor a2a de adenosina.
|
|
JP2005516891A
(ja)
*
|
2001-09-13 |
2005-06-09 |
シェーリング コーポレイション |
アデノシンＡ２ａレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ
|
|
PE20030477A1
(es)
|
2001-10-15 |
2003-06-06 |
Schering Corp |
ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
|
|
FR2832405B1
(fr)
*
|
2001-11-19 |
2004-12-10 |
Sanofi Synthelabo |
Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
PE20030739A1
(es)
|
2001-11-30 |
2003-08-28 |
Schering Corp |
Antagonistas del receptor de adenosina a2a
|
|
ATE358130T1
(de)
|
2001-11-30 |
2007-04-15 |
Schering Corp |
Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
|
|
JP4284182B2
(ja)
*
|
2001-11-30 |
2009-06-24 |
シェーリング コーポレイション |
アデノシンＡ２ａレセプターアンタゴニスト
|
|
PT2942082T
(pt)
|
2002-01-28 |
2019-06-06 |
Kyowa Hakko Kogyo Kk |
Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
|
|
AU2003245380A1
(en)
*
|
2002-05-30 |
2003-12-19 |
King Pharmaceuticals Research & Development, Inc. |
Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
|
|
US20060106040A1
(en)
*
|
2002-12-19 |
2006-05-18 |
Michael Grzelak |
Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
|
|
ES2354875T3
(es)
*
|
2002-12-19 |
2011-03-18 |
Schering Corporation |
Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal.
|
|
EP1618109A2
(en)
|
2003-04-09 |
2006-01-25 |
Biogen Idec MA Inc. |
Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
|
|
TWI375677B
(en)
*
|
2003-04-23 |
2012-11-01 |
Schering Corp |
2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
|
|
MXPA05013148A
(es)
*
|
2003-06-10 |
2006-03-17 |
Kyowa Hakko Kogyo Kk |
Un metodo de tratamiento de un trastorno de la ansiedad.
|
|
JP2006527212A
(ja)
*
|
2003-06-12 |
2006-11-30 |
ノボ ノルディスク アクティーゼルスカブ |
ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート
|
|
US7816353B2
(en)
*
|
2003-10-24 |
2010-10-19 |
Exelixis, Inc. |
P70S6 kinase modulators and method of use
|
|
PL1678182T3
(pl)
|
2003-10-28 |
2007-05-31 |
Schering Corp |
Sposób wytwarzania podstawionych 5-aminopirazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pirymidyn
|
|
DE602004009962T2
(de)
|
2003-12-01 |
2008-08-28 |
Schering Corp. |
Verfahren zur herstellung von substituierten 5-aminopyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidinen
|
|
CN100528162C
(zh)
*
|
2003-12-19 |
2009-08-19 |
先灵公司 |
药物组合物
|
|
US7709492B2
(en)
*
|
2004-04-21 |
2010-05-04 |
Schering Corporation |
Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
|
|
US7851478B2
(en)
|
2005-06-07 |
2010-12-14 |
Kyowa Hakko Kirin Co., Ltd. |
Agent for preventing and/or treating movement disorder
|
|
CN101312978A
(zh)
*
|
2005-09-19 |
2008-11-26 |
先灵公司 |
作为腺苷A2a受体拮抗剂的2－杂芳基－吡唑并－[4,3－e]－1,2,4－三唑并－[1,5－c]－嘧啶
|
|
AR056080A1
(es)
*
|
2005-09-23 |
2007-09-19 |
Schering Corp |
7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
|
|
ES2273599B1
(es)
|
2005-10-14 |
2008-06-01 |
Universidad De Barcelona |
Compuestos para el tratamiento de la fibrilacion auricular.
|
|
JP5539717B2
(ja)
*
|
2006-07-14 |
2014-07-02 |
塩野義製薬株式会社 |
オキシム化合物およびその使用
|
|
TW200840566A
(en)
*
|
2006-12-22 |
2008-10-16 |
Esteve Labor Dr |
Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
|
|
US7691869B2
(en)
|
2007-03-30 |
2010-04-06 |
King Pharmaceuticals Research And Development, Inc. |
Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
|
|
US8669260B2
(en)
*
|
2008-02-29 |
2014-03-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof
|
|
EP2262811B1
(en)
|
2008-03-04 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
|
|
US20110064671A1
(en)
|
2008-03-10 |
2011-03-17 |
Cornell University |
Modulation of blood brain barrier permeability
|
|
TWI473614B
(zh)
*
|
2008-05-29 |
2015-02-21 |
Kyowa Hakko Kirin Co Ltd |
Anti-analgesic inhibitors
|
|
NZ590793A
(en)
*
|
2008-07-23 |
2012-07-27 |
Kyowa Hakko Kirin Co Ltd |
Therapeutic agent for migraine
|
|
US20100093702A1
(en)
*
|
2008-10-13 |
2010-04-15 |
Barbay J Kent |
METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
|
|
US8273754B2
(en)
|
2008-12-30 |
2012-09-25 |
Arqule, Inc. |
Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
|
|
MX2011007678A
(es)
|
2009-01-20 |
2011-08-08 |
Schering Corp |
Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa.
|
|
EP2389362B1
(en)
|
2009-01-21 |
2019-12-11 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
BRPI1009398A2
(pt)
|
2009-03-13 |
2016-03-08 |
Advinus Therapeutics Private Ltd |
compostos de pirimidina fundida substituída
|
|
CA2756871A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted heterocyclic compounds
|
|
US8537177B2
(en)
*
|
2009-06-15 |
2013-09-17 |
Marvell World Trade Ltd. |
System and methods for gamut bounded saturation adaptive color enhancement
|
|
WO2011017299A2
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
|
|
KR101736218B1
(ko)
|
2009-09-25 |
2017-05-16 |
오리존 지노믹스 에스.에이. |
라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
|
|
EP2486002B1
(en)
|
2009-10-09 |
2019-03-27 |
Oryzon Genomics, S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
WO2011101861A1
(en)
|
2010-01-29 |
2011-08-25 |
Msn Laboratories Limited |
Process for preparation of dpp-iv inhibitors
|
|
WO2011106105A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
WO2011106573A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
ES2607081T3
(es)
|
2010-04-19 |
2017-03-29 |
Oryzon Genomics, S.A. |
Inhibidores de desmetilasa específica de lisina-1 y su uso
|
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
|
HUE037937T2
(hu)
|
2010-07-29 |
2021-11-29 |
Oryzon Genomics Sa |
Arilciklopropilamin-alapú LSD1-demetiláz inhibitorok és gyógyászati alkalmazásuk
|
|
CA2812378C
(en)
*
|
2010-09-24 |
2016-11-29 |
Advinus Therapeutics Limited |
Fused tricyclic compounds as adenosine receptor antagonist
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
WO2012107498A1
(en)
|
2011-02-08 |
2012-08-16 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
WO2012127472A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Mapi Pharma Ltd. |
Process and intermediates for the preparation of preladenant and related compounds
|
|
WO2012129381A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Concert Pharmaceuticals Inc. |
Deuterated preladenant
|
|
WO2013024474A1
(en)
*
|
2011-08-18 |
2013-02-21 |
Mapi Phrarma Ltd. |
Polymorphs of preladenant
|
|
EP2768805B1
(en)
|
2011-10-20 |
2020-03-25 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
PE20141692A1
(es)
|
2011-10-20 |
2014-11-08 |
Oryzon Genomics Sa |
Compuestos de (hetero) aril ciclopropilamina como inhibidores de lsd1
|
|
WO2014071512A1
(en)
*
|
2012-11-06 |
2014-05-15 |
Universite Laval |
Combination therapy and methods for the treatment of respiratory diseases
|
|
WO2014101120A1
(en)
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
|
US10472347B2
(en)
|
2014-11-18 |
2019-11-12 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with A2A antagonist properties
|
|
US10138212B2
(en)
|
2015-02-06 |
2018-11-27 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as A2A antagonist
|
|
EP3307067B1
(en)
|
2015-06-11 |
2022-11-02 |
Merck Sharp & Dohme LLC |
Aminopyrazine compounds with a2a antagonist properties
|
|
WO2017008205A1
(en)
|
2015-07-10 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Substituted aminoquinazoline compounds as a2a antagonist
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
CN115991679A
(zh)
*
|
2017-03-30 |
2023-04-21 |
伊忒欧斯比利时股份公司 |
作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物
|
|
WO2018178338A1
(en)
*
|
2017-03-30 |
2018-10-04 |
Iteos Therapeutics |
2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
|
|
WO2019118313A1
(en)
|
2017-12-13 |
2019-06-20 |
Merck Sharp & Dohme Corp. |
Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties
|
|
CA3087655A1
(en)
*
|
2018-01-04 |
2019-07-11 |
Impetis Biosciences Ltd. |
Tricyclic compounds, compositions and medicinal applications thereof
|
|
CN112384515A
(zh)
|
2018-02-27 |
2021-02-19 |
因赛特公司 |
作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
|
|
CN108276345A
(zh)
*
|
2018-03-22 |
2018-07-13 |
重庆奥舍生物化工有限公司 |
一种药物中间体嘧啶-5-甲醛的制备方法
|
|
EA202092036A1
(ru)
*
|
2018-04-08 |
2021-01-28 |
Бейджин, Лтд. |
Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a
|
|
JP7391046B2
(ja)
|
2018-05-18 |
2023-12-04 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
|
|
CN108864114B
(zh)
*
|
2018-06-04 |
2020-11-06 |
应世生物科技(南京)有限公司 |
选择性a2a受体拮抗剂
|
|
EP3818063A1
(en)
|
2018-07-05 |
2021-05-12 |
Incyte Corporation |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
|
CN110742893B
(zh)
*
|
2018-07-23 |
2024-04-05 |
百济神州(北京)生物科技有限公司 |
A2a受体拮抗剂治疗癌症的方法
|
|
EA202191498A1
(ru)
|
2018-11-30 |
2021-08-20 |
Мерк Шарп энд Доум Корп. |
9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
|
|
MX2021007426A
(es)
|
2018-12-20 |
2021-09-08 |
Incyte Corp |
Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina.
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020227156A1
(en)
*
|
2019-05-03 |
2020-11-12 |
Nektar Therapeutics |
Adenosine 2 receptor antagonists
|
|
DE102019116986A1
(de)
|
2019-06-24 |
2020-12-24 |
Helmholtz-Zentrum Dresden-Rossendorf E. V. |
Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
|
|
CN114667287A
(zh)
*
|
2019-07-17 |
2022-06-24 |
泰昂治疗公司 |
腺苷a2a受体拮抗剂及其用途
|
|
CN112592354B
(zh)
|
2019-07-30 |
2022-05-27 |
厦门宝太生物科技股份有限公司 |
一种异噁唑并嘧啶类杂环化合物的制备方法
|
|
CN112479956A
(zh)
|
2019-07-30 |
2021-03-12 |
杭州阿诺生物医药科技有限公司 |
一种用于制备腺苷受体抑制剂中间体的方法
|
|
CN111072675A
(zh)
*
|
2019-12-12 |
2020-04-28 |
广东东阳光药业有限公司 |
含氮稠合三环衍生物及其用途
|
|
JP7431665B2
(ja)
|
2020-05-20 |
2024-02-15 |
Ykk Ap株式会社 |
接合構造および建具
|
|
CN113773327B
(zh)
*
|
2021-09-13 |
2022-07-15 |
八叶草健康产业研究院(厦门)有限公司 |
一种吡唑并嘧啶并三唑环类化合物的制备方法
|
